Physician profile
Mengxi Chen
NPI 1457753717
$1,908.39
in general payments reported to CMS, 2019-2025
18 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.26 · 2024: $875 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.12 | 2024-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $200.91 | 2024-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $181.70 | 2024-2025 | Wainua, Airsupra, Farxiga |
| Abbvie INC. | $169.80 | 2025 | |
| Exact Sciences Corporation | $153.71 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $138.76 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.22 | 2024-2025 | Jardiance, Ofev, Tradjenta |
| Lilly USA, LLC | $86.27 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $76.28 | 2024 | |
| Glaxosmithkline, LLC. | $65.01 | 2022-2025 | Trelegy Ellipta |
| Pfizer INC. | $57.77 | 2025 | |
| Daiichi Sankyo INC. | $57.40 | 2024 | Injectafer, Vanflyta |
| Sumitomo Pharma America, INC. | $52.36 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $40.93 | 2024 | Quviviq |
| Eisai INC. | $31.18 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.88 | 2025 | Cardiomems |
| Axsome Therapeutics, INC. | $18.23 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $14.86 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mengxi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.